IceCure Medical Ltd.
Business
IceCure Medical Ltd. develops and commercializes liquid nitrogen-based cryoablation systems for minimally invasive treatment of benign and malignant tumors, with a lead focus on breast tumors. Its main products include the ProSense and IceSense3 systems, the XSense platform, disposable CryoProbes and introducers, and related service and maintenance offerings. The company operates product development, clinical/regulatory and commercial channels, pursuing next-generation systems such as MSense and recurring disposable probe sales. It markets and distributes its systems and consumables across the United States, Europe, Canada, China, Asia, Latin America and other international markets through hospitals, clinics, investigator-led trials and distributors.
Summary from filing dated 2025-03-27
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $3.38M |
| Net income | $-15.06M |
| Total assets | $13.89M |
| Total liabilities | — |
| Stockholders' equity | $9.05M |
| Operating cash flow | $-14.57M |